Literature DB >> 12065737

Putative conventional protein kinase C inhibitor Gödecke 6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] stimulates transglutaminase activity in primary mouse epidermal keratinocytes.

Brian A Shapiro1, Sagarika Ray, EunMi Jung, William T Allred, Wendy B Bollag.   

Abstract

Much data in the literature suggest a role for protein kinase C (PKC) in regulating keratinocyte proliferation and differentiation. Nevertheless, the exact role of this family of isoenzymes is unclear, since PKC agonists (e.g., phorbol esters) are known to stimulate expression of both proliferative and differentiative markers in keratinocytes. Similarly, PKC inhibitors have been demonstrated both to inhibit [2-[1-3(aminopropyl)indol-3-yl]-3(1-methyl-1H-indol-3-yl)maleimide, acetate (Ro 31-7549) and 3-[1-[3-(amidinothio)propyl-1H-indol-3-(1-methyl-1H-indol-3yl) maleimide (Ro 31-8220)] and to induce (staurosporine) keratinocyte differentiation. In this study, we examined the role of the PKC inhibitor, Gödecke 6976 (Gö6976) [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo (3,4-c)-carbazole], on keratinocyte proliferation, as measured by DNA synthesis, and differentiation, as monitored by transglutaminase activity. This compound is reported to be selective for the conventional PKC isoforms, of which keratinocytes express only PKCalpha, and for protein kinase D (PKD; also known as PKCmu). We report that Gö6976 stimulated transglutaminase activity. Consistent with this effect, Gö6976 also potently inhibited [(3)H]thymidine incorporation (a half-maximal inhibitory concentration of approximately 0.1 microM). In addition, Gö6976 (1 microM) was able to enhance the stimulation of transglutaminase activity by 1,25-dihydroxyvitamin D(3) but had no effect on D(3)-induced expression of keratin-1. Conversely, Gö6983 [2-[1-(3-dimethylaminopropy)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)maleimide], a similar compound that also selectively inhibits conventional PKCalpha, but not PKD, had little or no effect on DNA synthesis or transglutaminase activity (up to 1 microM). The effect of Gö6976 was not due to cytotoxicity as its effect on thymidine incorporation was largely reversible, and its stimulation of transglutaminase activity could be inhibited by another general PKC inhibitor, bisindolylmaleimide I. Therefore, our results suggest a proproliferative, antidifferentiative role for PKD in epidermal maturation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065737     DOI: 10.1124/jpet.302.1.352

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Protein kinase D as a potential new target for cancer therapy.

Authors:  Courtney R LaValle; Kara M George; Elizabeth R Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  Biochim Biophys Acta       Date:  2010-05-24

2.  Protein kinase D1 deficiency promotes differentiation in epidermal keratinocytes.

Authors:  Vivek Choudhary; Lawrence O Olala; Ismail Kaddour-Djebbar; Inas Helwa; Wendy B Bollag
Journal:  J Dermatol Sci       Date:  2014-10-02       Impact factor: 4.563

3.  The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors.

Authors:  Senthil Nathan Arun; Ding Xie; M Ernest Dodd; Xiaofeng Zhong; Wendy B Bollag
Journal:  J Dermatol Sci       Date:  2010-08-10       Impact factor: 4.563

4.  PKCdelta-mediated regulation of FLIP expression in human colon cancer cells.

Authors:  Qingding Wang; Xiaofu Wang; Yuning Zhou; B Mark Evers
Journal:  Int J Cancer       Date:  2006-01-15       Impact factor: 7.396

5.  A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle.

Authors:  Ezra E W Cohen; Hongyan Zhu; Mark W Lingen; Leslie E Martin; Wen-Liang Kuo; Eugene A Choi; Masha Kocherginsky; Joel S Parker; Christine H Chung; Marsha Rich Rosner
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

6.  Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis.

Authors:  Sarah M Thomas; Andrei Purmal; Michael Pollastri; Kojo Mensa-Wilmot
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.